logo
Plus   Neg
Share
Email

IntelGenx Signs LOI With Tilray To Produce Cannabis-Infused VersaFilm Products

IntelGenx Corp. (IGX.V, IGXT.OB), an oral drug delivery company, announced Thursday that it has executed a non-binding letter of intent or LOI with Tilray, Inc. (TLRY), a cannabis research, cultivation, production and distribution company, to enter into a world-wide agreement to produce cannabis-infused VersaFilm products.

The LOI also contemplates that, at the time of entering into the definitive agreement, Tilray will make a strategic investment in IntelGenx by way of a non-brokered private placement. Tilray will purchase 1.25 million shares of IntelGenx at a price of $0.80 per share, which is equal to the five-day volume weighted average closing price of IntelGenx' common stock on the OTCQX for the period ended September 18.

IntelGenx intends to use the proceeds from the Private Placement for cannabis-infused VersaFilm product development in connection with the LOI. The Private Placement will be subject to the approval of the TSX Venture Exchange.

The companies plan to co-develop and commercialize oral film products infused with recreational and medical cannabis,in anticipation of amended cannabis regulations which would allow adult-use consumers to purchase edible products.

Pursuant to the LOI, subject to entering into a definitive agreement and the satisfaction of customary closing conditions, IntelGenx and Tilray will fund 20% and 80% of the costs associated with the development of the cannabis-infused VersaFilm products, respectively.

IntelGenx will have rights to manufacture and supply the co-developed products to Tilray, and will also receive a fixed single-digit royalty on net product sales. Tilray will have the exclusive, worldwide marketing and distribution rights for the co-developed products.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Goldman Sachs Group, Inc. (GS) reported earnings per common share of $6.28 for the third quarter of 2018 compared to $5.02 for the third quarter of 2017. On average, 22 analysts polled by Thomson Reuters expected the company to report profit per share of $5.38 for the quarter. Analysts' estimates... Johnson & Johnson (JNJ) on Tuesday, while reporting financial results for the third quarter, raised its adjusted earnings and sales forecast for fiscal 2018. The company raised full-year outlook for adjusted earnings to a range of $8.13 to $8.18 per share. This reflects an increase in expected operational... Bahrain's foreign minister has called for a boycott of Uber after the ride-hailing company's Chief Executive Officer Dara Khosrowshahi said he will not attend an investment conference in Bahrain's ally, Saudi Arabia. Khosrowshahi is among several business leaders who have said they are pulling out of the three-day investment conference slated to take place in Saudi Arabia beginning October 23.
Follow RTT